Bioventus Continues to Excel: Strong Q3 Results and Growing Momentum in Key Growth Drivers
As reported on the company's recent Q3 2026 conference call, Bioventus has maintained its positive momentum, delivering a solid financial performance and encouraging leading indicators across its growth drivers.
In his opening remarks, Rob Claypoole, President and CEO of Bioventus, highlighted the company's continued focus on accelerating long-term revenue growth through increased investment in four key growth drivers: peripheral nerve stimulation, platelet-rich plasma, ultrasonics, and international business. He also emphasized the importance of increasing earnings even with higher levels of investment in these areas, as well as continuing to strengthen cash flow and enhance capital allocation optionality.
The company's third quarter revenue grew 3%, led by strong growth of 6% in Pain Treatments. This performance was partially offset by softness in bone graft substitutes within Surgical Solutions, which continued to face near-term headwinds. However, excluding BGS, revenue growth for the rest of the business was 6% for the quarter, reflecting strong underlying momentum within each of the growth drivers.
One area where Bioventus is seeing significant progress is in platelet-rich plasma (PRP), which has been a key focus for the company. The number of capital placements continues to grow sequentially, and the company is pleased to see the growing adoption of its customizable PRP solution. In fact, revenue from PRP disposable kits exceeded revenue from capital placements during the third quarter, an important indicator of future growth.
This success in PRP is not limited to medical applications; Bioventus has also recently secured exclusive rights from its partner, APEX Biologix, to offer its solution in sports medicine accounts. This move further underscores the company's commitment to expanding its presence in key markets and driving growth through innovative partnerships.
Overall, Bioventus' Q3 results demonstrate the company's ability to execute on its strategic priorities and drive sustainable long-term value for shareholders. As the company continues to navigate the evolving healthcare landscape, it is well-positioned to capitalize on emerging opportunities and build on its momentum in key growth drivers."
